Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with ComirnatyⓇ: A randomized, observer-blind, controlled, phase 1 study.
Sow SO, Tapia MD, Haidara FC, Diallo F, Han X, Chen J, Shi L, Yang Q, Yu B, Hu Y, Yuan L, Liu G, Grappi S, Monti M, Viviani S, Ji M, Zhou C. Sow SO, et al. Among authors: yu b. Int J Infect Dis. 2024 Nov;148:107237. doi: 10.1016/j.ijid.2024.107237. Epub 2024 Sep 11. Int J Infect Dis. 2024. PMID: 39270925 Free article. Clinical Trial.
Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
Li J, Shi LW, Yu BW, Huang LR, Zhou LY, Shi L, Jiang ZW, Xia JL, Wang XY, Li RC, Yuan L, Li YP, Li CG. Li J, et al. Vaccine. 2023 May 5;41(19):3141-3149. doi: 10.1016/j.vaccine.2023.04.009. Epub 2023 Apr 13. Vaccine. 2023. PMID: 37061370 Free article. Clinical Trial.
Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females.
Shi LW, Li J, Yu BW, Huang LR, Li K, Ji M, Zhou LY, Yuan L, Yang SY, Chen JJ, Wang L, Jiang ZW, Li RC, Li YP, Xia JL, Mo ZJ, Li CG. Shi LW, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2209001. doi: 10.1080/21645515.2023.2209001. Epub 2023 May 30. Hum Vaccin Immunother. 2023. PMID: 37249310 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Feng GW, Wang ZF, He P, Lan QY, Ni L, Yang YZ, Wang CF, Cui TT, Huang LL, Yan YQ, Jiang ZW, Yang Q, Yu BW, Han X, Chen JJ, Yang SY, Yuan L, Zhou LY, Liu G, Li K, Huang Z, Zhao JC, Hu ZY, Xie ZQ. Feng GW, et al. Hum Vaccin Immunother. 2023 Aug;19(2):2262635. doi: 10.1080/21645515.2023.2262635. Epub 2023 Oct 26. Hum Vaccin Immunother. 2023. PMID: 37881130 Free PMC article. Clinical Trial.
Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.
Li J, Shi LW, Li K, Huang LR, Li JB, Dong YL, Li W, Ji M, Yang Q, Zhou LY, Yuan L, Yan XM, Chen JJ, Jiang ZW, Qi YY, Li RC, Li YP, Xia JL, Yu BW, Mo ZJ, Li CG. Li J, et al. Vaccine. 2023 Oct 26;41(48):7212-9. doi: 10.1016/j.vaccine.2023.10.041. Online ahead of print. Vaccine. 2023. PMID: 39492306 Free PMC article.
12,472 results
You have reached the last available page of results. Please see the User Guide for more information.